iBio Reports Preliminary Unaudited Fiscal Year 2022 : vimars

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation...

Related Keywords

United States , Texas , American , Tom Isett , Company Guide Section , Fastpharming Contract Development , Drug Administration , Bio Inc , Company Special Meeting Of Stockholders , Rubryc Therapeutics Inc , Exchange Commission , Company Annual Report On Form , Company Certificate Of Incorporation , Manufacturing Services , Sm Development Services , Manufacturing System , Business Developments , Rubryc Therapeutics , Discovery Engine , Investigational New Drug , Science Translational Medicine , Corporate Developments , Special Meeting , Unaudited Financial Results , Fraunhofer United States , Annual Report , Guide Section , Nyse Ibio , Bio , Nc ,